Fibrosis, the Bad Actor in Cardiorenal Syndromes: Mechanisms Involved

Area of Science:

• Cardiology
• Nephrology
• Pathophysiology

Background:

• Cardiorenal syndrome describes the bidirectional relationship between cardiac and renal diseases.
• Renal dysfunction significantly impacts cardiac disease prognosis, and kidney disease patients exhibit high cardiovascular comorbidity rates.
• Fibrosis is a key feature in organ injury progression and a potential driver of cardiorenal syndrome pathophysiology.

Purpose of the Study:

• To review pathophysiological pathways contributing to fibrotic damage in cardiorenal syndromes.
• To identify mechanisms and potential therapeutic targets for preventing fibrosis development.
• To summarize the roles of inflammation, oxidative stress, and endoplasmic reticulum stress in mediating fibrosis.

Main Methods:

• Literature review focusing on pathophysiological mechanisms of fibrosis in cardiorenal syndrome.
• Analysis of studies investigating inflammation, oxidative stress, and endoplasmic reticulum stress as triggers of fibrosis.
• Synthesis of current understanding regarding fibrosis as a driver and marker in cardiorenal syndromes.

Main Results:

• Inflammation, oxidative stress, and endoplasmic reticulum stress are identified as key triggers and mediators of fibrosis in cardiorenal syndromes.
• Fibrosis is implicated not only as a marker but also as a significant driver of the disease progression.
• Understanding these pathways may reveal targets for therapeutic intervention.

Conclusions:

• Fibrosis plays a critical role in the pathophysiology of cardiorenal syndrome.
• Targeting inflammation, oxidative stress, and endoplasmic reticulum stress may offer novel strategies for managing cardiorenal fibrosis.
• Further research into these mechanisms is warranted for developing effective treatments.